Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location | |
|---|---|---|---|---|
|
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study |
Sickle Cell Disease | Phase4 |
Belgium Germany Italy Lebanon Oman Spain United States View All
|
NCT04657822 |
|
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 |
Argentina Austria Brazil Bulgaria Canada China Czechia Denmark France Germany Italy Malaysia Mexico Oman Poland Portugal Romania Russia South Korea Spain Turkey (Türkiye) United Kingdom United States Vietnam View All
|
NCT04877522 |
|
Asciminib RMP Study |
Chronic Myeloid Leukemia | South Korea | NCT05943522 | |
|
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea |
Non-Small-Cell Lung Carcinoma | South Korea | NCT05703516 | |
|
CAR-T Long Term Follow Up (LTFU) Study |
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Phase3 |
Australia Austria Belgium Canada Denmark Finland France Germany Hong Kong Israel Italy Japan Norway Singapore South Korea Spain Taiwan United Kingdom United States View All
|
NCT02445222 |
|
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab |
Extensive Stage Small Cell Lung Cancer | Phase1, Phase2 |
Austria Canada China Czechia France Germany Hong Kong Israel Italy Singapore South Korea Spain Taiwan United Kingdom United States View All
|
NCT05142696 |
|
Special Drug Use-results Surveillance of Tafinlar/Mekinist |
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor | Japan | NCT06262919 | |
|
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. |
Metastatic Neuroendocrine Prostate Cancer | Phase1 |
France Germany Italy Spain United Kingdom United States View All
|
NCT06379217 |
|
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. |
Non-Small Cell Lung Carcinoma | Phase4 | India | NCT05110196 |
|
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis |
Multiple Sclerosis | Phase4 |
Germany Italy Poland Puerto Rico United Kingdom United States View All
|
NCT06444113 |